



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/517,381	08/22/2005	Nobuya Kaneko	04208.0210	3951
22852 7590 05/17/2007 FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER LLP 901 NEW YORK AVENUE, NW WASHINGTON, DC 20001-4413			EXAMINER GAMI, TEJAL	
			ART UNIT 2121	PAPER NUMBER
			MAIL DATE 05/17/2007	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/517,381

Applicant(s)

KANEKO ET AL.

Examiner

Tejal J. Gami

Art Unit

2121

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 09 February 2007.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 6 and 9-12 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 6 and 9-12 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date <u>11/16/2006</u> | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

1. This office action is responsive to an AMENDMENT entered February 9, 2007 for the patent application 10/517381.

Status of Claims

2. Claim 6 was rejected in the last Office Action dated September 11, 2006.

As a response to the September 11, 2006 office action, Applicant has amended Claim 6; and added claims 9-12.

Claims 6 and 9-12 are now pending in this office action.

Claim Rejections - 35 USC § 102

3. The previous rejections under 35 U.S.C. 102 are withdrawn in response to Applicant's amendments to the claims.
4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

5. Claims 6 and 9-12 are rejected under 35 U.S.C. 102(e) as being anticipated by Rocci et al. (WO 01/65441).

As to independent claim 6, Rocchi discloses a medicine prototype support system for an ingredient manufacturer developing medical product (e.g., pharmaceutical) at a request of a product manufacturer (see Page 5, First Paragraph) comprising:

a database comprising confidential (e.g., authorization; granted access) first main ingredient information and corresponding second main ingredient information (e.g., direct fit) (see Page 5, Last two Paragraphs), the first confidential (e.g., authorization; granted access) main ingredient information being confidential information of the product manufacturer (see Page 5, Second Paragraph);

information conversion means for selecting a second main ingredient by comparing (e.g., comparison 809) properties of the confidential main ingredient stored in the database with properties of a plurality of potential second main ingredients stored in the database (see Figure 8 for "a flow diagram of a general process for a user to sort through a formulation database to select a set of matching formulations);

composition ingredient determination means for selecting a composition ingredient based on the properties of the first and second main ingredients (see Page 8, Section 1. Formulation Know-How); and

communication means (e.g., server) for receiving confidential-first main ingredient information from a product manufacturer (e.g., privately maintained formulation data) (see Page 11, Last Line of Second Paragraph) and for transmitting selected second main ingredient information (e.g., formulation) and composition (e.g., components) ingredient information to a composition manufacturer system (e.g.,

customer for assembly) (see Page 13, Third Paragraph of Section 6. Formulation System), wherein the medicine prototype support system does not reveal the identity of the confidential first main ingredient to the composition manufacturer system (e.g., privately maintained formulation data) (see Page 11, Last Line of Second Paragraph).

As to independent claim 9, Rocchi discloses a medicine prototype support system for an ingredient manufacturer developing medical product (e.g., pharmaceutical) at a request of a product manufacturer (see Page 5, First Paragraph) comprising:

- a database including first main ingredient information and second main ingredient information (e.g., direct fit) (see Page 5, Last two Paragraphs);

- information conversion software that selects a second main ingredient by comparing (e.g., comparison 809) properties of the first main ingredient stored in the database with properties of a plurality of potential second main ingredients stored in the database (see Figure 8 for "a flow diagram of a general process for a user to sort through a formulation database to select a set of matching formulations);

- composition ingredient determination software that selects a composition ingredient based on the properties of the first and second main ingredients (see Page 8, Section 1. Formulation Know-How); and

- a server for transmitting second main ingredient information and composition ingredient information to a composition manufacturer system (see Page 10, Last Paragraph), wherein the first main ingredient information is confidential information of the product manufacturer (e.g., privately maintained formulation data) (see Page 11,

Last Line of Second Paragraph), the second main ingredient information is non-confidential (e.g., granted access to formulations the affiliates decide to make available to them) (see Page 5, Last Line of Second Paragraph), and the medicine prototype support system does not reveal the identity of the confidential first main ingredient to the composition manufacturer system (e.g., privately maintained formulation data) (see Page 11, Last Line of Second Paragraph).

As to independent claim 10, Rocchi discloses a method of requesting prototype manufacture from a composition manufacturer (see Page 5, First Paragraph) comprising the steps of:

receiving a request from a product manufacturer, the request including main ingredient information that is confidential (e.g., authorization; granted access) information of the product manufacturer (see Page 5, Last two Paragraphs);

storing (e.g., stored in the system database) the confidential first main ingredient information (see Page 5, Last two Paragraphs);

selecting a second main ingredient by comparing (e.g., comparison 809) the properties of the confidential main ingredient with the properties of a plurality of potential second main ingredients (see Figure 8 for "a flow diagram of a general process for a user to sort through a formulation database to select a set of matching formulations);

determining a composition ingredient based on the confidential main ingredient information and second main ingredient information (see Page 8, Section 1. Formulation Know-How);

transmitting a request for prototype manufacture to the composition manufacturer (e.g., customer for assembly) (see Page 13, Third Paragraph of Section 6. Formulation System), the request for prototype manufacture including the identities of the selected second main ingredient (e.g., formulation) and the selected composition ingredient (e.g., components) (see Page 13, Third Paragraph of Section 6. Formulation System); and maintaining the confidentiality of the first main ingredient information by not transmitting it to the composition manufacturer (e.g., privately maintained formulation data) (see Page 11, Last Line of Second Paragraph).

As to dependent claim 11, Rocchi teaches the method of claim 10, further comprising transmitting a second request for prototype manufacture to a second composition manufacturer (see Page 7, First Paragraph of Detailed Description of the Invention).

As to dependent claim 12, Rocchi teaches the method of claim 10, wherein the confidential main ingredient information received from the product manufacturer (e.g., privately maintained formulation data) (see Page 11, Last Line of Second Paragraph) includes the identity of the main ingredient (e.g., formulations are developed by combining ingredients) (see Page 8, First Sentence of Section 1. Formulation Know-How).

Response to Arguments

6. Applicant's arguments filed February 9, 2007 are moot in light of new grounds of rejections necessitated by the amendment.

Conclusion

7. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tejal J. Gami whose telephone number is (571) 270-1035. The examiner can normally be reached on Monday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Knight can be reached on (571) 272-3687. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 2121

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Anthony Knight
Supervisory Patent Examiner
Tech Center 2100

TJG
TJG


DAVID VINCENT 5/14/07
SUPERVISORY PATENT EXAMINER